PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Not tonight deer: A new birth control vaccine helps reduce urban deer damage

2011-09-01
(Press-News.org) Contact: Michael Bernstein
m_bernstein@acs.org
303-228-8532 (Aug. 25-Sept. 1)
202-872-6042 (Before Aug. 25) Michael Woods
m_woods@acs.org
303-228-8532 (Aug. 25-Sept. 1)
202-872-6293 (Before Aug. 25) American Chemical Society
Not tonight deer: A new birth control vaccine helps reduce urban deer damage DENVER, Aug. 31, 2011 — A new birth control vaccine for white-tailed deer — a growing nuisance in urban areas for gardens and landscaping — eliminates the dangerous reproductive behavior behind the annual autumn surge in automobile-deer collisions. The vaccine, just becoming commercially available in some states, was the topic of a report here today at the 242nd National Meeting & Exposition of the American Chemical Society (ACS).

Named GonaCon™, the vaccine also shows promise for reducing or eliminating some of the undesirable behaviors in household pets and farm animals that have not been spayed or neutered. Among them: scent-marking, fighting, caterwauling and wandering in cats, and aggressive behavior in horses. That's because GonaCon™ blocks the action of the male and female sex hormones, testosterone and estrogen, that spark such behaviors. It also has potential applications in prairie dogs, wild horses and feral dogs.

David A. Goldade, who reported on the vaccine, said that blocking action is one of GonaCon™'s multiple advantages over other birth control methods developed to cope with the population explosion of white-tailed deer in many parts of the country. In addition to the damage to gardens and expensive landscaping plants, deer in urban areas can attract mountain lions and other predators into residential areas. And on both urban and rural roads, 1.5 million deer-auto collisions kill at least 150 people annually and cause more than $1 billion in property damage.

"Other birth-control vaccines using porcine zona pellucida (PZP) also can prevent deer from producing offspring, but PZP-vaccinated animals still exhibit mating behaviors," Goldade explained. He is with the U. S. Department of Agriculture's (USDA's) Animal and Plant Health Inspection Service/Wildlife Services National Wildlife Research Center (NWRC) in Fort Collins, Colo., where GonaCon™ was developed. "That opens the door to dangerous situations in which males chase females across the highway. With GonaCon™, however, vaccinated deer don't even try to mate," Goldade continued.

Goldade explained that GonaCon™ blocks a biological signal that triggers reproductive behavior in deer and many other mammals in temperate areas of the world. As day length decreases in autumn, the reproductive systems in these animals "turn on." Testosterone levels rise in males, and females go into estrus, or "heat." Gonadotropin-releasing hormone (GnRH), produced in a gland at the base of the brain, issues the biochemical orders for increased production of the sex hormones estrogen, progesterone and testosterone. Without GnRH, the body makes little or none of those hormones.

The GnRH vaccine induces the body to make antibodies against its own GnRH, thus destroying the signal for sex and inducing infertility in both males and females. USDA studies with white-tailed deer and other animals — free-ranging California ground squirrels, captive Norway rats, domestic and feral swine and wild horses— established the effectiveness of a single injection of GnRH. The effects in penned white-tailed deer lasted up to five years without a booster vaccination.

To use the vaccine on wild deer populations, the researchers first had to register it with the U.S. Environmental Protection Agency (EPA). One requirement for registration is data on the concentration of the active ingredient, in this case, GnRH. Goldade's team developed a test using a standard laboratory technique called mass spectrometry to do just that.

GonaCon™ is the only EPA-registered multi-year, single-injection wildlife contraceptive for female white-tailed deer population control, but don't expect to see it on store shelves next to the deer and squirrel repellents. It also has to be registered in a state and must be administered by a USDA or state game and fish department staff member, who captures, tranquilizes and injects deer one by one. So far, only Maryland and New Jersey have approved it for use within their borders.

### The American Chemical Society is a non-profit organization chartered by the U.S. Congress. With more than 163,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society contact newsroom@acs.org.

ABSTRACT: Wildlife populations continue to grow despite the use of traditional management efforts. GonaCon™ is an immunocontraceptive vaccine used to reduce reproduction in mammalian species, including white-tailed deer (Odocoileus virginianus). The vaccine consists of synthetic gonadotropin releasing hormone (GnRH) conjugated to a mollusk hemocyanin (Concholepas concholepas) prepared as an emulsion with mineral oil to promote a prolonged immune response. Development of an analytical method for determination of the active ingredient in the vaccine formulation was complicated by the emulsion and conjugation of GnRH to the carrier protein. Breaking the emulsion was achieved chemically by addition of ethyl ether. The aqueous portion containing the GnRH conjugate was cleaved enzymatically with a protease (clostripain) at the arginine-proline site of its peptide sequence. Hydrolysis produced a diagnostic eight amino acid peptide fragment which was unique to GnRH and easily quantified by LC/MS/MS. Typical recoveries of fortified samples at the target concentration exceeded 90%.


ELSE PRESS RELEASES FROM THIS DATE:

Choice of seizure drug for brain tumor patients may affect survival

2011-09-01
ST. PAUL, Minn. – New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures. The research is published in the August 31, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology. "Despite some limitations, our results suggest that the choice of seizure medications in brain tumor patients should be carefully considered as it may give people a few more months with their loved ones," said study ...

Malaria discovery gives hope for new drugs and vaccines

Malaria discovery gives hope for new drugs and vaccines
2011-09-01
An investigation into the mysterious inner workings of the malaria parasite has revealed that it survives and proliferates in the human bloodstream thanks in part to a single, crucial chemical that the parasite produces internally. According to scientists at the University of California, San Francisco (UCSF) and Stanford Medical School, reporting today in the journal PLoS Biology, this insight immediately provides a powerful new tool for discovering and designing drugs to treat malaria, which infects hundreds of millions of people around the world each year and claims ...

Resistance to antibiotics is ancient, McMaster study finds

2011-09-01
Hamilton, ON (August 31, 2011) – Scientists were surprised at how fast bacteria developed resistance to the miracle antibiotic drugs when they were developed less than a century ago. Now scientists at McMaster University have found that resistance has been around for at least 30,000 years. Research findings published today in the science journal Nature show antibiotic resistance is a natural phenomenon that predates the modern clinical antibiotic use. Principal investigators for the study are Gerry Wright, scientific director of the Michael G. DeGroote Institute for Infectious ...

Physicists at the center of police weapons testing

2011-09-01
In this month's edition of Physics World, David Wilkinson, visiting fellow at Nottingham Trent University and former project manager in the UK Home Office Scientific Development Branch, explains how physics is at the forefront of police weapons testing, making sure that potential devices meet the strict criteria set out by the UK government. Modern police weapons, such as CS gas and TASERs, are often referred to as "less-lethal weapons" because they are designed to effectively stop people with minimum risk to both suspects and officers, and are less brutal than traditional ...

World's largest cardiac arrest trial shows longer initial paramedic CPR provides no benefit

Worlds largest cardiac arrest trial shows longer initial paramedic CPR provides no benefit
2011-09-01
A study involving nearly 10,000 cardiac arrest patients from 10 North American regions has shown that extending the period of initial cardiopulmonary resuscitation (CPR) by paramedics and firefighters from one to three minutes provides no benefit. The study, led by Dr. Ian Stiell of the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa) and the Resuscitation Outcomes Consortium (ROC), resolves a worldwide controversy about cardiac arrest care. It is the largest randomized cardiac arrest trial in the world, published in the New England Journal ...

New biochemical discoveries into developing disease

2011-09-01
Researchers have undertaken the most comprehensive investigation of genetic variance in human metabolism and discovered new insights into a range of common diseases. Their work has revealed 37 new variants that are associated with concentrations of metabolites in the blood. Many of these match variants associated with diseases such as chronic kidney disease, type 2 diabetes and blood clotting. The team conducted the largest ever study of the human genome for genetic variants associated with metabolites - the biochemical compounds representing the start or end of metabolic ...

Humans shaped stone axes 1.8 million years ago, study says

Humans shaped stone axes 1.8 million years ago, study says
2011-09-01
A new study suggests that Homo erectus, a precursor to modern humans, was using advanced toolmaking methods in East Africa 1.8 million years ago, at least 300,000 years earlier than previously thought. The study, published this week in Nature, raises new questions about where these tall and slender early humans originated and how they developed sophisticated tool-making technology. Homo erectus appeared about 2 million years ago, and ranged across Asia and Africa before hitting a possible evolutionary dead-end, about 70,000 years ago. Some researchers think Homo erectus ...

The star that should not exist

The star that should not exist
2011-09-01
A faint star in the constellation of Leo (The Lion), called SDSS J102915+172927 [1], has been found to have the lowest amount of elements heavier than helium (what astronomers call "metals") of all stars yet studied. It has a mass smaller than that of the Sun and is probably more than 13 billion years old. "A widely accepted theory predicts that stars like this, with low mass and extremely low quantities of metals, shouldn't exist because the clouds of material from which they formed could never have condensed," [2] said Elisabetta Caffau (Zentrum fur Astronomie der Universitat ...

Bedrock nitrogen may help forests buffer climate change, study finds

Bedrock nitrogen may help forests buffer climate change, study finds
2011-09-01
For the first time, researchers at the University of California, Davis, have demonstrated that forest trees have the ability to tap into nitrogen found in rocks, boosting the trees' growth and their ability to pull more carbon dioxide from the atmosphere. Given that carbon dioxide is the most important climate-change gas, the nitrogen in rocks could significantly affect how rapidly the earth will warm in the future, the researchers say. They report their findings in the Sept. 1 issue of the scientific journal Nature. If trees can access more nitrogen than previously ...

Results of world-first viral therapy trial in cancer patients published in Nature

Results of world-first viral therapy trial in cancer patients published in Nature
2011-09-01
VIDEO: This three-dimensional reconstruction of part of a human colorectal tumor shows widespread infection with oncolytic vaccinia virus (green). Click here for more information. Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other institutions today reported promising results of a world-first cancer therapy trial in renowned journal Nature. The trial is the first to show that an intravenously-delivered ...

LAST 30 PRESS RELEASES:

Modulation of antiviral response in fungi via RNA editing

Global, regional, and national burden of nontraumatic subarachnoid hemorrhage

Earliest use of psychoactive and medicinal plant ‘harmal’ identified in Iron Age Arabia

Nano-scale biosensor lets scientists monitor molecules in real time

Study shows how El Niño and La Niña climate swings threaten mangroves worldwide

Quantum eyes on energy loss: diamond quantum imaging for next-gen power electronics

Kyoto conundrum: More hotels than households exist in ancient capital

Cluster-root secretions improve phosphorus availability in low-phosphorus soil

Hey vespids, what's for dinner? DNA analysis of wasp larvae’s diverse diet

Street smarts: how a hawk learned to use traffic signals to hunt more successfully

Muscle quality may hold clues to early cognitive decline

Autophagy and lysosomal pathways orchestrate unconventional secretion of Parkinson’s disease protein

Mystery of “very odd” elasmosaur finally solved: one of North America’s most famous fossils identified as new species

Half the remaining habitat of Australia's most at-risk species is unprotected

Study reveals influence behind illegal bear bile consumption in Việt Nam

Satellites offer new view of Chesapeake Bay’s marine heat waves

Experimental drug may benefit some patients with rare form of ALS

Early testing could make risky falls a thing of the past for elderly people

A rule-breaking, colorful silicone that could conduct electricity

Even weak tropical cyclones raise infant mortality in poorer countries, USC-led research finds

New ketamine study promises extended relief for depression

Illinois physicists develop revolutionary measurement tool, exploiting quantum properties of light

Moffitt to present plenary and late-breaking data on blood, melanoma and brain metastases at ASCO 2025

Future risk of wildfire and smoke in the South

On-site health clinics boost attendance in rural classrooms

Ritu Banga Healthcare Disparities Research Awards support innovative science

New tools to treat retinal degenerations at advanced stages of disease

Brain drain? More like brain gain: How high-skilled emigration boosts global prosperity

City of Hope researchers to present cancer advances that could boost survival at the American Society of Clinical Oncology (ASCO) Annual Meeting

A new approach could fractionate crude oil using much less energy

[Press-News.org] Not tonight deer: A new birth control vaccine helps reduce urban deer damage